- Jan 31, 2019
Daunorubicin reduces cardiomyopathy risk compared with doxorubicin in childhood cancer survivors
Daunorubicin appeared associated with a lower cardiomyopathy risk than doxorubicin among childhood cancer survivors, according to a multicenter cohort study published in JAMA Oncology. Read more: https://www.healio.com/hematology-oncology/pediatric-oncology/news/in-the-journals/%7Bc480352e-3ab4-42b1-b33e-4e049f3371b3%7D/daunorubicin-reduces-cardiomyopathy-risk-compared-with-doxorubicin-in-childhood-cancer-survivors
- Jan 31, 2019
International Research Team Led by Australian Scientists Discover a Potential Way to Treat and Preve
Discovering this link – by which MYCN controls polyamine levels in cancer cells, driving the growth and proliferation of the neuroblastoma cells – means that scientists for the first time have a potential therapeutic "way in" to disrupting cancer cell growth. Read more: https://www.prnewswire.com/news-releases/international-research-team-led-by-australian-scientists-discover-a-potential-way-to-treat-and-prevent-cancer-in-children-with-neuroblastoma-300786554.html
- Jan 24, 2019
Cancer-slaying virus may fight childhood eye tumor
Curing the childhood eye cancer retinoblastoma often comes at a cost. The tumor, which sprouts in the retina and primarily occurs in children under the age of 5, is fatal if not treated. Yet chemotherapy can cause permanent vision loss, and patients sometimes need surgery to remove one or both eyes. Now, scientists have found that a cancer-slaying virus seems to combat this cancer in mice without serious side effects. Read more: https://www.sciencemag.org/news/2019/01/cancer-
- Jan 24, 2019
New tumor test could guide personalized treatment for children with cancer
Scientists at the University of British Columbia and BC Children's Hospital are the first in Canada to use a new test for pediatric tumour analysis that may one day guide personalized treatments for children with cancer. Read more: https://medicalxpress.com/news/2019-01-tumor-personalized-treatment-children-cancer.html
- Jan 17, 2019
Engineered immune cells target broad range of pediatric solid tumors in mice
In mouse studies, a Stanford-led team has developed an engineered immune cell that eliminates several types of childhood tumors. The innovation may help patients with relapsed or metastatic disease. Read more: http://med.stanford.edu/news/all-news/2019/01/engineered-immune-cells-target-broad-range-of-pediatric-tumors.html
- Jan 17, 2019
Researchers identify multiple new subtypes of most common childhood cancer
Researchers used integrated genomic analysis, including RNA sequencing, to define the genomic landscape of B-cell acute lymphoblastic leukemia (B-ALL) in almost 2,000 children and adults. Read more: https://www.news-medical.net/news/20190114/Researchers-identify-multiple-new-subtypes-of-most-common-childhood-cancer.aspx
- Jan 15, 2019
What Price Do Families Pay When a Child has Cancer?
New research by POGO is linking data from its cancer registry (POGONIS) to copies of Canadian tax returns stored at Statistics Canada. Families who experience a diagnosis of childhood cancer are being compared to families who do not experience cancer and are similar in age to the parents, in number and age of the children, where they live and income at the time of diagnosis. Read more: https://www.pogo.ca/what-price-do-families-pay-when-a-child-has-cancer/
- Jan 10, 2019
Cardiotoxic childhood cancer treatment boosts heart failure risk at young age
Childhood cancer survivors who received cardiotoxic treatment are at high risk of heart failure at a young age, researchers say. Read more: https://www.mdlinx.com/internal-medicine/top-medical-news/article/2019/01/10/7552936/
- Jan 10, 2019
What is to blame for childhood cancer? We often misunderstand the reality
A new study by UNSW medical researchers sheds light on an understudied area – community beliefs about what causes cancer in children. Read more: https://newsroom.unsw.edu.au/news/health/what-blame-childhood-cancer-we-often-misunderstand-reality
- Jan 3, 2019
Lead Researcher Highlights Tisagenlecleucel Benefit in Younger Leukemia Patients
The CD19-targeted CAR T-cell therapy, tisagenlecleucel (Kymriah) demonstrated durable remissions in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Read more: https://www.onclive.com/web-exclusives/lead-researcher-highlights-tisagenlecleucel-benefit-in-younger-leukemia-patients